Adipocytokines are not associated with gestational diabetes mellitus but with pregnancy status.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
07 2020
Historique:
received: 13 01 2020
revised: 12 03 2020
accepted: 01 04 2020
pubmed: 14 4 2020
medline: 9 9 2021
entrez: 14 4 2020
Statut: ppublish

Résumé

Adipose tissue-secreted proteins, i.e. adipocytokines, have been identified as potential mediators linking fat mass and adipose tissue dysfunction with impaired glucose homeostasis, alterations in the inflammatory status, and risk of diabetes. The aim of this study was to determine whether seven circulating adipocytokines are associated with gestational diabetes mellitus (GDM) or are altered by metabolic and weight changes during pregnancy itself. A panel of seven adipocytokines (i.e. adiponectin, adipocyte fatty acid-binding protein, chemerin, leptin, Pro-Enkephalin, progranulin, and Pro-Neurotensin) was quantified in serum in a cross-sectional cohort of 222 women with the following three groups matched for age and body mass index: (i) 74 pregnant women with GDM; (ii) 74 pregnant women without GDM; and (iii) 74 non-pregnant and healthy women. A stepwise statistical approach was used by performing pairwise comparisons, principal component analysis (PCA), and partial least square discriminant analysis (PLS-DA). Five out of seven adipocytokines were dysregulated between pregnant and non-pregnant women, i.e. adiponectin, chemerin, leptin, Pro-Enkephalin, and progranulin. None of the adipocytokines significantly differed between GDM and non-GDM status during pregnancy. The same five adipocytokines clustered in a principal component representing pregnancy-induced effects. Fasting insulin was the most relevant parameter in the discrimination of GDM as compared to pregnant women without GDM, whereas chemerin and adiponectin were most relevant factors to discriminate pregnancy status. Pregnancy status but not presence of GDM can be distinguished by the seven investigated adipocytokines in discrimination analyses.

Identifiants

pubmed: 32283441
pii: S1043-4666(20)30104-6
doi: 10.1016/j.cyto.2020.155088
pii:
doi:

Substances chimiques

Adipokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

155088

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest MSch receives funding from Pfizer Inc. for a project not related to this research. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Thomas Ebert (T)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany; Leipzig University Medical Center, IFB AdiposityDiseases, 04103 Leipzig, Germany; Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, Stockholm, Sweden. Electronic address: Thomas.ebert@medizin.uni-leipzig.de.

Claudia Gebhardt (C)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany.

Markus Scholz (M)

Leipzig University Medical Center, IFB AdiposityDiseases, 04103 Leipzig, Germany; University of Leipzig, Institute of Medical Informatics, Statistics and Epidemiology, Leipzig, Germany.

Dorit Schleinitz (D)

Leipzig University Medical Center, IFB AdiposityDiseases, 04103 Leipzig, Germany.

Matthias Blüher (M)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany; Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.

Michael Stumvoll (M)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany.

Peter Kovacs (P)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany; Leipzig University Medical Center, IFB AdiposityDiseases, 04103 Leipzig, Germany.

Mathias Fasshauer (M)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany; Leipzig University Medical Center, IFB AdiposityDiseases, 04103 Leipzig, Germany; Justus-Liebig-University, Institute of Nutritional Science, 35390 Giessen, Germany.

Anke Tönjes (A)

University of Leipzig Medical Center, Medical Department III - Endocrinology, Nephrology, Rheumatology, 04103 Leipzig, Germany. Electronic address: Anke.toenjes@medizin.uni-leipzig.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH